OTD provides independent consulting services in oncology early drug development.
We offer integrated drug discovery services and routinely conduct contract preclinical research.
The OTD team has collective experience managing over 50 Phase I-II oncology clinical trials.
A CRO focused solely on oncology, specialized in the early development of single agent and combination anticancer regimens.
Our goal is to support our partners to establish a clinical development plan to generate data in a timely, efficient and cost-effective manner.
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.
Oncotarget. 2015 May 14
100 rue Martre
92110 Clichy - FRANCE
Tel: +33 1 47 15 01 01
Fax: +33 1 45 19 06 59